QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Genmab
(NASDAQ:GMAB)
30.83
-0.25[-0.80%]
At close: May 23
30.83
00
After Hours: 4:00PM EDT
Day High/Low30.73 - 31.11
52 Week High/Low27.42 - 49.07
Open / Close31.03 / 30.83
Float / Outstanding- / 655.1M
Vol / Avg.353.9K / 669.6K
Mkt Cap20.2B
P/E61.38
50d Avg. Price34.48
Div / Yield-
Payout Ratio-
EPS0.71
Total Float-

Genmab (NASDAQ:GMAB), Quotes and News Summary

Genmab (NASDAQ: GMAB)

Day High/Low30.73 - 31.11
52 Week High/Low27.42 - 49.07
Open / Close31.03 / 30.83
Float / Outstanding- / 655.1M
Vol / Avg.353.9K / 669.6K
Mkt Cap20.2B
P/E61.38
50d Avg. Price34.48
Div / Yield-
Payout Ratio-
EPS0.71
Total Float-
Benzinga - 6 days ago
Benzinga - May 12, 2022, 4:41AM
Benzinga - May 11, 2022, 11:04AM
Benzinga - May 2, 2022, 8:41AM
Benzinga - Apr 19, 2022, 6:41AM
Benzinga - Apr 14, 2022, 6:09AM
Benzinga - Apr 13, 2022, 5:31PM
Benzinga - Apr 12, 2022, 9:53AM
Benzinga - Apr 8, 2022, 12:10PM
Benzinga - Apr 7, 2022, 7:46PM
Benzinga - Mar 8, 2022, 7:36AM
Benzinga - Mar 2, 2022, 6:27AM
Benzinga - Feb 17, 2022, 4:52AM
Benzinga - Feb 16, 2022, 11:06AM
Benzinga - Jan 31, 2022, 6:51AM
Benzinga - Jan 4, 2022, 9:06AM
Benzinga - Jan 3, 2022, 10:05AM
Benzinga - Dec 13, 2021, 6:04AM
Benzinga - Dec 1, 2021, 6:21AM
Benzinga - Nov 4, 2021, 5:06PM
load more
Sector: Health Care.Industry: Biotechnology
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered wth Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-10
REV
Q1 2022Est.ActualSurprise
EPS0.11
REV319.590M319.668M78.000K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Genmab Questions & Answers

Q
How do I buy Genmab (GMAB) stock?
A

You can purchase shares of Genmab (NASDAQ: GMAB) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Genmab's (GMAB) competitors?
Q
What is the target price for Genmab (GMAB) stock?
A

The latest price target for Genmab (NASDAQ: GMAB) was reported by Morgan Stanley on Tuesday, May 17, 2022. The analyst firm set a price target for 29.00 expecting GMAB to fall to within 12 months (a possible -5.94% downside). 12 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Genmab (GMAB)?
A

The stock price for Genmab (NASDAQ: GMAB) is $30.83 last updated May 23, 2022, 8:00 PM UTC.

Q
Does Genmab (GMAB) pay a dividend?
A

There are no upcoming dividends for Genmab.

Q
When is Genmab (NASDAQ:GMAB) reporting earnings?
A

Genmab’s Q2 earnings are confirmed for Wednesday, August 10, 2022.

Q
Is Genmab (GMAB) going to split?
A

There is no upcoming split for Genmab.

Q
What sector and industry does Genmab (GMAB) operate in?
A

Genmab is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.